Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: Pfizer | Vintage Vibes

Inside David Denton's Nike Pay Package: $7.25M Cash, $11.5M Stock Awards and a Turnaround Mandate

Nike's new CFO David Denton could earn up to $25.9m (£19.6m) in year one, including $7.25 million cash he must repay if he leaves within two years.

International Business Times UK

Women say contraceptive jab complications ‘life-changing’ at MSP meeting

Pfizer’s Depo-Provera has been previously linked to an increased risk of a type of brain tumour.

Evening Standard

Pfizer CFO Dave Denton to leave company in August

Pfizer's finance chief Dave Denton is leaving on August 15. Cecile Guegan will be the interim chief financial officer. Denton's departure raises investor concerns about Pfizer's 2026 forecast and succession plans. The company is preparing to enter the obesity drug market. Pfizer's shares were down in early trading. A search…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

The Drug Pricing Machine and Why Patients Keep Paying More

Roughly a third of American adults report difficulty paying for prescription drugs, and many are forced to skip doses, delay refills, or abandon treatment altogether.

International Business Times

‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic?

Internationally renowned for their life-saving Covid vaccine, what is Moderna doing now? Their CEO joins us in the studio to discuss bioterrorism, pandemic preparedness and cancer treatment.

Euronews

These 3 Quality Stocks Will Make You Want to LEAP on Their Calls

Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality stocks stood out.

Barchart

The First Lyme Disease Vaccine in 24 Years Just Passed Its Pivotal Phase 3 Trial with 74 Percent Efficacy — and It Is for Children Too

Pfizer and Valneva announced Phase 3 VALOR trial results for Lyme disease vaccine PF-07307405 on March 23, 2026: 73.2–74.8% efficacy in ages 5 and older. Regulatory submissions planned for 2026. No Lyme vaccine has been available in the U.S. since 2002.

Medical Daily

Read news from The Economist, FT, and more,
with one subscription

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

MarketBeat

Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase

Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics portfolio, a newly expanded biosimilars platform and specialty product launches. Speaking at a Gol

MarketBeat

Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052

Aclaris Therapeutics (NASDAQ:ACRS) executives outlined a busy clinical calendar for the biotechnology company during a fireside chat at the Jefferies 2026 Global Healthcare Conference, highlighting upcoming readouts across its immunology pipeline and a planned Phase 2 asthma study for its lead bispe

MarketBeat

How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks?

Due to Pfizer’s underperformance relative to its peers over the past year, Wall Street analysts remain cautious about the stock’s prospects

Barchart

Igor Taldenko: "A Website Outage Today Is an Event That Affects People's Lives"

An engineer with over 12 years of experience working with high-load systems explains why a website outage is no longer just a bug — it's an event capable of derailing transactions, delaying payments, and even impacting people's health — and how to build architecture that minimizes these risks.

inkl

3 Dividend Stocks Yielding Above 5% to Scoop Up Now

These three dividend stocks combine strong yields with resilient businesses.

Barchart

False claims link hantavirus to COVID vaccines

Social media users are claiming that hantavirus was listed as a side effect of the COVID-19 vaccine, but that's a misreading of the facts.

AAP

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Lyme disease cases in England rise by more than 20% in a year

Scientists developing vaccines and anti-tick treatments amid growing concern over spread of disease

The Independent UK

Debunked Bill Gates tick theory resurfaces through MAHA social media claims

IN FULL

The Independent UK

MAHA’s latest conspiracy? Blaming Bill Gates for spike in tick bites

The number of tick-related visits to emergency rooms has hit the highest level in the U.S. in nearly a decade

MarketBeat

BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Valneva Q1 Earnings Call Highlights

Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer. Chief Executive Officer Thomas Lingelbach

MarketBeat

Arvinas Q1 Earnings Call Highlights

Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation. President and Chief Executive Officer Randy Teel said the app

International Business Times

White House Says Trump's Drugmaker Deals Could Save U.S. Economy $529 Billion Over 10 Years

The White House said on Tuesday that agreements with major drugmakers could save the U.S. economy $529 billion over the next decade.

Barchart

Stock Index Futures Climb as U.S.-Iran Ceasefire Holds, JOLTs Report and Earnings in Focus

June S&P 500 E-Mini futures (ESM26) are up +0.28%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.47% this morning, supported by lower oil prices as the ceasefire in the Middle East appeared to be holding.

Barchart

Are Wall Street Analysts Bullish on Pfizer Stock?

Pfizer has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Barchart

Wall Street Says Buy Merck Over Pfizer. The Numbers Tell a More Complicated Story.

A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term upside.

Reason

The COVID Reckoning Doesn't Go Far Enough

Real medical freedom will require something greater than replacing the public health establishment: ending the FDA's monopoly.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.